Form 4 for GYRE GYRE THERAPEUTICS, INC.
Accepted 2026-05-07 21:58:29 ET · period of report 2026-05-05 · accession 0001140361-26-019658 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2026-05-07 21:58 | 2026-05-05+ | GYRE | Luo Ying | CEO, Dir | S - Sale | $8.04 | -10.3K | 2.57M | -0.4% | -$82.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-05 | S | D | 179 | $8.01 | 2,575,362 | I By Spouse | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025. |
| 2 | Common | Common Stock | 2026-05-06 | S | D | 10,136 | $8.04 | 2,565,226 | I By Spouse | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025. (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.071. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |